Trials / Completed
CompletedNCT00849550
Safety and Dosage Study of RAD001 (Everolimus) in Combination With Current Standard of Care to Treat Advanced Solid Tumors.
A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and RAD001 (XELOX-A-Ev) for Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Herbert Hurwitz · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if RAD001 (everolimus) helps improve the standard treatment of XELOX-A (bevacizumab, oxaliplatin, capecitabine) in advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev) | bevacizumab IV, capecitabine oral, oxaliplatin IV, RAD001 oral |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2009-02-24
- Last updated
- 2012-12-24
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00849550. Inclusion in this directory is not an endorsement.